WEBULL
WebtradeDownload

Positive Cancer Trial Data Could Be A Big Moment For Celcuity (CELC)

Simply Wall St · 1d ago
  • Celcuity reported new subgroup data from the VIKTORIA 1 Phase 3 trial in breast cancer and updated Phase 1b/2 results in metastatic castration resistant prostate cancer, with gedatolisib based combinations showing improved progression free outcomes, higher response rates and manageable safety compared with standard regimens in the studied populations.
  • The lower discontinuation rates and transient Grade 3 stomatitis seen with gedatolisib, alongside activity in both PIK3CA mutant breast tumors and prostate cancer regardless of PTEN status, sharpen the picture of how this drug could be used across multiple solid tumor settings.
  • We will now look at how Celcuity’s investment narrative is shaped by these new gedatolisib efficacy and tolerability signals across cancers.
Spot 36 healthcare AI stocks that, like Celcuity, are trying to turn targeted therapies and data driven drug development into the next wave of oncology breakthroughs.

Celcuity Investment Narrative Recap

Owning Celcuity means believing gedatolisib can convert strong breast cancer data into durable commercial uptake while the business manages heavy upfront spending and negative equity. The recent subgroup readouts strengthen that scientific story but do not change the near term reality. Regulatory timing, payer decisions and physician adoption still sit at the center of what moves this stock next.

In the short run, the key trigger remains regulatory progress and clarity on how VIKTORIA 2 and other studies feed into label expansions. The biggest risk is that approval timing or usage is slower or narrower than management is building toward, which would leave elevated operating costs and debt sitting against delayed product revenue.

The VIKTORIA 1 subgroup analysis in PIK3CA mutant breast cancer is the release that ties closest to the central catalyst. It showed gedatolisib based triplet and doublet regimens with longer progression free outcomes, higher objective response rates and lower discontinuation from treatment emergent events than alpelisib plus fulvestrant in the studied groups. That kind of differentiation is what any future commercial launch will likely lean on.

Those details matter for execution. Better tolerability, including low and transient Grade 3 stomatitis and minimal discontinuations, can be important for physicians choosing between oral PI3K therapies and an intravenous option. If regulators agree with the risk benefit profile, this dataset could support positioning gedatolisib in second line HR positive, HER2 negative disease and influence how much of the US$5b to US$6b addressable market Celcuity can realistically reach.

Celcuity’s current loss of $192.9 million in earnings is set against analyst forecasts that call for $817.9 million in revenue and $267.5 million in earnings by 2029, which implies roughly a 32.7% profit margin on those future sales and an earnings swing of about $460 million from today’s level.

Uncover why Celcuity's fair value indicates a 132% potential upside to its current price, which could narrow quickly.

NasdaqCM:CELC 1-Year Stock Price Chart
NasdaqCM:CELC 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate view focuses less on trial success and more on adoption risk. You see the new Celcuity data, yet the most cautious analysts were only penciling in about US$602.1 million of revenue and roughly US$103.8 million of earnings by 2029. That is a far more restrained story. It shows how sharply opinions can differ and why it can be useful to compare several pre news forecasts as you decide which narrative feels closest to your own expectations.

Explore 3 other Celcuity fair value estimates, including one that suggests it could be worth just $154.72!

Form Your Own Verdict

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking for more investment ideas beyond Celcuity?

Once you have a view on Celcuity, it can help to widen the lens and compare it with other opportunities that match your preferred balance of risk, balance sheet strength and income potential.

  • If you want potential upside without stretching your budget, scan through 9 elite penny stocks with strong financials that might fit a higher risk, higher reward style of investing.
  • For investors who care most about quality at a sensible price, focus on 30 high quality undervalued stocks that pair stronger fundamentals with what could be more modest expectations baked into their valuations.
  • If capital preservation is front of mind, start with 30 resilient stocks with low risk scores that score well on stability so you can compare steadier profiles against a higher risk oncology stock like Celcuity.